Last reviewed · How we verify
XELOX + bevacizumab
Oxaliplatin and capecitabine inhibit DNA replication and transcription, while bevacizumab targets vascular endothelial growth factor.
Oxaliplatin and capecitabine inhibit DNA replication and transcription, while bevacizumab targets vascular endothelial growth factor. Used for Metastatic colorectal cancer, Metastatic gastric cancer.
At a glance
| Generic name | XELOX + bevacizumab |
|---|---|
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Platinum-based chemotherapy, Antimetabolite, Monoclonal antibody |
| Target | DNA, Thymidylate synthase, VEGF |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, thereby inhibiting DNA replication and transcription. Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), preventing its interaction with its receptor and thereby inhibiting angiogenesis.
Approved indications
- Metastatic colorectal cancer
- Metastatic gastric cancer
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
- Hand-foot syndrome
- Hypertension
Key clinical trials
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (PHASE3)
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (PHASE2)
- FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis (PHASE2)
- Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis (PHASE2)
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers (PHASE2)
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (PHASE2)
- Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer (PHASE2)
- Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |